EUCTR2004-005276-16-SE进行中（未招募）不适用
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. - N/A
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •.• Female, age 18 or older
- •Histologically proven epithelial ovarian cancer, epithelial fallopian tube cancer, or primary peritoneal cancer
- •Prior treatment with only 1 chemotherapy regimen, including adjuvant therapy, which must be platinum-based and may include sequential maintenance therapy or second look debulking surgery (no gaps in administration of initial therapy may occur other than a delay no longer than 2 months for treatment toxicity).
- •Eastern Cooperative Oncology Group performance status is equal to or less than 2
- •Estimated life expectancy of at least 3 months
- •Recurrence or progression after 6 full cycles of a complete 6 cycle initial treatment regimen or 6 months after the beginning (first dose) of the to include
- •- Subjects with platinum-resistant disease (platinum-free interval from the end of first-line treatment less than 6 months)
- •- Subjects with platinum-sensitive disease (platinum-free interval from the end of first-line treatment equal to or more than 6 months) who are not expected to benefit from or who are ineligible for or who are not willing to receive retreatment with platinum-based chemotherapy
- •Measurable disease that can be evaluated by RECIST guidelines for response or progression or both and documented by radiographic methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scan. Date of radiological evidence is the documented date of progression
- •Must be able to receive dexamethasone or its equivalent
- •Adequate organ function as evidenced by the following peripheral blood counts or serum chemistry values within 7 days before randomization:
- •hemoglobin =9 g/dL
- •absolute neutrophil count (ANC) =1,500/µL, and
- •platelet count =100,000/µL
- •serum creatinine =1.5 mg/dL (=132.6 µmol/L) or creatinine clearance =60 mL/min
- •creatine phosphokinase (CPK) =upper limit of normal (ULN)
- •Hepatic function variables
- •Total bilirubin =1.5 ULN, direct bilirubin =ULN
- •Total alkaline phosphatase (ALP) =1.5 ULN, or if >1.5 ULN, then ALP liver fraction or 5’ nucleotidase must be =ULN
- •AST and ALT must be =2.5 × ULN
- •Left ventricular ejection fraction (LVEF) by baseline multigated acquisition (MUGA) scan or 2-d echocardiogram must be within normal limits for the institution (see Section 6.2.2)
- •Adequately recovered from the acute toxicity from any prior treatment
- •Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •At investigative sites that are participating in the optional CellSearch, pharmacogenomic, or protein testing portion of this protocol, the subject (or their legally acceptable representative) must sign the informed consent forms for CellSearch enumeration alone, or for additional pharmacogenomic testing, utilizing CellSearch, additional blood or paraffin samples or serum for DNA, mRNA, and protein expression analysis. These informed consent documents will indicate whether or not
- •the subject wishes to participate in these parts of the study. Participation in the pharmacogenomics and CellSearch aspects of this study is not mandatory.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects treated with more than 1 prior chemotherapy regimen (including adjuvant therapy)
- •Refractory disease, defined as disease progression within 6 months of the beginning (first dose) of the initial line of platinum-based chemotherapy for ovarian cancer
- •Isolated rise in CA-125 without documented radiological evidence of disease progression
- •Prior exposure to anthracyclines for ovarian cancer or to YONDELIS or hypersensitivity to the pharmacologically active substance or to any of the excipients
- •Subjects unwilling or unable to have a central venous catheter, which is required if randomly assigned to treatment with YONDELIS + DOXIL
- •Subjects of child bearing potential not employing adequate contraception, which may include prescription contraceptives (oral, injection, or patch), intrauterine device, double-barrier method or male partner sterilization (not applicable to subjects that are surgically sterile) or subjects who are lactating.
- •Less than 4 weeks from radiation or experimental therapy, less than 2 weeks from last dose of hormonal therapy, or less than 3 weeks from prior chemotherapy or biological therapy.
- •History of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated) unless in remission for 5 years or more
- •Known hypersensitivity to doxorubicin or to excipients in the formulations of either DOXIL or YONDELIS.
- •Known clinically relevant central nervous system metastasis
- •Active viral hepatitis or history of liver disease
- •Myocardial infarct within 6 months before enrollment, New York Heart Association (NYHA) Class II or greater heart failure (Attachment 1), uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
- •Any other unstable medical conditions, such as:
- •- Uncontrolled diabetes
- •- Psychiatric disorder (including dementias) that prevents compliance with protocol
- •- Uncontrolled seizures
- •- Acute deep vein thrombosis requiring intravenous or subcutaneous therapeutic anticoagulant therapy (chronic coumadin or prophylactic subcutaneous heparin allowed)
- •- Active infection.
研究者
相似试验
进行中（未招募）
1 期
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. - N/AAdvanced relapsed ovarian cancerMedDRA version: 9.1 Level: LLT Classification code 10033130 Term: Ovarian cancer NOSEUCTR2004-005276-16-GBPharma Mar S.A.650
进行中（未招募）
不适用
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. - N/AEUCTR2004-005276-16-BEPharma Mar S.A.650
进行中（未招募）
不适用
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. - N/AAdvanced relapsed ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSEUCTR2004-005276-16-DEPharma Mar S.A.650
进行中（未招募）
1 期
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS™ with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer.Advanced relapsed ovarian cancerMedDRA version: 5.0Level: DTClassification code 10033130EUCTR2004-005276-16-ESPharma Mar S.A. Sociedad Unipersonal650
进行中（未招募）
不适用
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX alone in subjects with advanced relapsed ovarian cancer - NDFemale subjects 18 years of age or older with advanced ovarian cancer who have met the specific inclusion and exclusion criteria will be enrolled in this study. Subjects must have histologically proven epithelial ovarian or primary peritoneal cancer previously treated with only 1 chemotherapy regimen (platinum-based) and have experienced either recurrence or progression more than 6 months after the beginning (first dose) of the initial line of platinum-based chemotherapy for ovarian cancer.MedDRA version: 9.1Level: LLTClassification code 10057529Term: Ovarian cancer metastaticEUCTR2004-005276-16-ITPHARMA MAR650